CJC-1295 (DAC)
CJC-1295 with DAC (Drug Affinity Complex) is a long-acting GHRH analogue engineered for sustained GH and IGF-1 elevation. The DAC technology binds the peptide to serum albumin, extending its half-life to approximately 8 days from a single administration.
CJC-1295 (DAC) — Scientific Overview
CJC-1295 with DAC incorporates a reactive succinimide linker at lysine 33 that forms a covalent bond with serum albumin after injection. This albumin binding dramatically extends half-life from 30 minutes to approximately 6–8 days.
The extended half-life produces sustained GHRH receptor stimulation and continuous elevation of GH and IGF-1 for up to a week per injection. This sustained action profile is fundamentally different from pulsatile GHRH analogues, producing a baseline GH elevation model rather than discrete pulses.
Published research demonstrated 2–10× increases in mean GH concentrations and 1.5–3× increases in IGF-1 lasting more than 6 days post-injection in healthy adults. The depot-like action enables sustained GH axis stimulation research without daily administration.
Store lyophilized at -20°C. Reconstituted solution stable 14 days at 2–8°C. The DAC modification does not affect standard peptide storage conditions.
Related Compounds
⚗️ Aeterion Labs — All products are for research purposes only. Not for human use. Not intended to diagnose, treat, cure, or prevent any disease.